Alps Group Inc
ALPS
NASDAQ·Healthcare·Biotechnology·Mkt cap $63.2M
$0.38
▲ 0.00%
P/E
—
Mkt Cap
$63.2M
52-Wk Range
$0.23–$2.90
52-Week Range
$0.23 - $2.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 96.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated platform combining R&D, clinical services, and wellness solutions
- Focus on accessible precision and predictive medicine
- Advanced therapeutic development capabilities
- Patient-centric healthcare ecosystem model
Bear Case
1 risk
- Low volatility (beta -0.1).
Growth
No forward estimates available
Increasing demand for precision medicine and personalized treatment
Value
Valuation data unavailable
Momentum
Falling
-47.0% over 3m
Quality
Stable
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ALPS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Most recent quarter reported revenue of $0. Reported EPS of -$0.24.
Reported EPS · last 4Q
Q3 25
-$0.24
Q2 25
-$0.24
Q1 25
-$0.20
Q4 24
-$0.05
Revenue trend · last 7Q
—
—
—
—
—
—
—
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
$0
$0
$0
$0
$0
$0
$0
Margins · last 7Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ALPS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related